Skip to content
naulon
Get started
No noticeNo retraction, correction or concern found when last checked on Oct 26, 2026.

Podophyllotoxin: History, Recent Advances and Future Prospects

Zinnia Shah, Umar Farooq Gohar, Iffat Jamshed and 7 more

Biomolecules · 2021 · Review · CC BY

doi:10.3390/biom11040603 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Podophyllotoxin, along with its various derivatives and congeners are widely recognized as broad-spectrum pharmacologically active compounds. Etoposide, for instance, is the frontline chemotherapeutic drug used against various cancers due to its superior anticancer activity. It has recently been redeveloped for the purpose of treating cytokine storm in COVID-19 patients. Podophyllotoxin and its naturally occurring congeners have low bioavailability and almost all these initially discovered compounds cause systemic toxicity and development of drug resistance. Moreover, the production of synthetic derivatives that could suffice for the clinical limitations of these naturally occurring compounds is not economically feasible. These challenges demanded continuous devotions towards improving the druggability of these drugs and continue to seek structure-optimization strategies. The discovery of renewable sources including microbial origin for podophyllotoxin is another possible approach. This review focuses on the exigency of innovation and research required in the global R&D and pharmaceutical industry for podophyllotoxin and related compounds based on recent scientific findings and market predictions.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 26, 2026. Paragraph numbers are ours, so an answer can point at one.

1. Introduction

Podophyllotoxin is an aryltetralin-type lignan isolated from species of Podophyllum. Two most common sources are the rhizomes of Podophyllum peltatum (American mayapple) and Sinopodophyllum hexandrum Royle (Barberry family). These perennial herbs are distributed widely across the Himalayan region and Western China. Plants with high podophyllotoxin or podophyllotoxin-analogues’ content have been extensively used in traditional medicine since a long time in different cultures. This remarkable molecule was first isolated in 1880 by Podwyssotzki, while it had already been described as early as in 1753 by Linnaeus. Due to its remarkable biological activity, podophyllotoxin has remained a subject of various investigations ever since. It is mainly obtained from the alcohol-soluble fraction of Podophyllum species, called podophyllin—a bitter tasting resin.

The podophyllotoxin extract has been documented for its use as a laxative, and as a remedy for various medical complications such as gonorrhea, tuberculosis, menstrual disorders, psoriasis, dropsy, cough, syphilis and venereal warts. The podophyllotoxin-family is now confirmed to elicit various curative properties such as mitotoxic, neurotoxic, insecticidal, antimicrobial, anti-inflammatory, antispasmogenic, hypolipidemic, immunosuppressive, antioxidative, analgesic and cathartic activities. Initial studies reporting its pronounced activity against cancer cells established greater interest in its antimitotic efficacy. The clinical practicality of podophyllotoxin was, however, largely tampered because of its undesirable secondary effects such as gastrointestinal toxicity, neurotoxicity, hair-loss, and bone marrow suppression, etc., which led to the finding of less-toxic derivatives or analogues. These molecules have since become a structural base for the development of new therapeutic agents.

Podophyllotoxin (C22H22O8) is a selective cyclolignan whose structure was first elucidated in 1930s. Extensive structural modifications of podophyllotoxin have culminated to eventually discover clinically viable anticancer drugs, namely; etiposide, teniposide and etopophos, but it was not until twenty years after the discovery of these viable derivatives that their mechanism of action was understood. Podophyllotoxins were recognized to interact with the DNA and its replication process to carry out their antimitotic effects. Etiposide, for instance, inhibits DNA topoisomerase II (dnaTII) and causes cell cycle arrest in the S-phase. Podophyllotoxin is also known to prevent cell growth through inhibiting the polymerization of tubulin and thus subdue the configuration of mitotic spindles. The therapeutic use of these drugs is however, in fact, hindered by myelosuppression, development of drug-resistance and their cytotoxic activity towards normal body cells. On these accounts, the synthesis of new potent podophyllotoxin-derivatives such as NK-611, NPF, GL-311, TOP-53, F14512, azatoxin, etc., is a continuing concern—structures of some of these derivatives are shown in Figure 1. These have thence opened a window for virtual designing of unlimited podophyllotoxin-derivatives geared at improving clinical efficacy. These studies necessitate reviewing all the recent advancement made on podophyllotoxin. Furthermore, the extinction of podophyllotoxin plant sources shifted the focus towards source alternatives, which includes the manipulation of microbes for the purpose. This review is aimed at providing an insight to podophyllotoxin research and hence helps delineate further investigations, which are needed in this field.

2. Structural Characteristics of Podophyllotoxin

Podophyllotoxin has a five-ring system (ABCDE) having four chiral centers (C1-C4) in a row—Figure 2. There are five important structural characteristics of most podophyllotoxin species: (1) a tetracyclic group going from dioxole ring (A) to the lactone ring (D); (2) four oxygen atoms located at the functional groups lactone, methoxys, secondary alcohol and oxoles; (3) ring E with alpha-configuration located at position 1; (4) four asymmetrical adjacent centers and (5) the unique stereochemical properties of C4 define the molecules’ mechanism of action. Studies have revealed, rational modification at C4 can improve the molecule’s topoisomerase II inhibitory activity, drug resistance profile, water solubility and antimitotic activities. The lactone ring is known to exhibit transconfiguration, which easily epimerizes in low basic conditions.

3. Derivatives, Analogues and Hybrids of Podophyllotoxin

Derivatives of this multifaceted molecule are synthesized as properties of its four rings. Ring A, for instance is not essential for the exhibition of antimitotic activity, and aromatization of ring C may cause displacement of axially positioned ring E—leading to a loss of cytotoxic property. Structural diversity hence brings many attractive medicinal properties and a comprehensive insight to the molecule’s mechanism of action. These derivatives were first introduced by Schreier through selective cleavage of ring A to produce a 6, 7-dihydroxy derivative (compound A), which was further methylated with diazomethane to produce yet another derivative (compound B) shown in Figure 3. Schreier’s methods were later on slightly modified to produce a large group of podophyllotoxin derivativescompound I–XXfrom compound C, Figure 3. However, the structural modifications are not alone to contribute towards the novelty of the derivatives, instead, changes in the chemical skeleton of podophyllotoxin cyclo-lignan add particularity to each individual derivative.

With slight modifications in the podophyllotoxin skeleton, the ring-A-open compounds appeared biologically less active than podophyllotoxin itself; functional studies indicate that an intact A-ring system is important for the compounds’ DNA topoisomerase II (dtopII) inhibiting activity. Based on these findings, three crucially significant domains in the parent pharmacophore model were reported. Modifications at these domains further revealed the unexplored potential of novel clinically applicable derivatives (shown in Figure 4)with a mechanism of action distinct to that of the previously well-established derivative; etiposide. The paucity of studies on B-ring modifications in podophyllotoxin led the investigation of α-peltatin and β-peltatin. These two compounds (Figure 5) exhibited significant antiviral and antitumor activities. In order to investigate the influence of B-ring substitutions and modifications, a series of ester- and ether-derivatives of both structures were prepared by various researchers but were reported to be biologically less active than their parent compounds.

Several C-ring modified podophyllotoxin analogues have also been subjected to extensive research. Unlike the two natural C-aromatized lignans; justicidin A and diphyllin; the many synthetic C-ring aromatized compounds were prepared but reported to have no cytotoxic activities. This observation proposed that the axial E-ring conformation was lost during synthetic preparations. The loss of the axial E-ring conformation is now known to be directly linked to the loss of molecule’s cytotoxic and dtopII inhibiting activity. Notably, however, delactonized analogues of podophyllotoxin—apopicropodophyllotoxin; and its beta-isomer—β-apopicropodophyllotoxin give strong antimitotic activities, otherwise indicating the untrammelled antimitotic potential of podophyllotoxin-like compounds in the absence of the lactone ring. The antitumor activity of podophyllotoxin and its derivatives is mainly due to the ability to inhibit tubulin polymerization, which is a property of the axially placed E-ring. The cis-fused lactone rings, however, modulating its selectivity from tubulin to IGF-1 (insulin- like growth factor I) receptor to trigger cell death.

Transfused γ-lactone D ring is also strict requirement for podophyllotoxin’s antitumor activity. Since it is susceptible to isomerization, the opening of this lactone ring is undesirable for it limits the physiological lifetime of these compounds and their biological effectiveness as well. A series of delactonized D-ring derivatives were prepared and studied by various researchers, most of which were found to be less cytotoxic than the parent compound itself. However, an ethyl hydrazide derivative (Figure 6) was found to retain its clinical efficacy but was discontinued due to severe adverse aftereffects. Studies that later discovered immunosuppressive ability of these derivatives were attempted to revive D-ring modified podophyllotoxin—antitumor drug preparations. 4′-d-β-DMEP (4′-d-β-Demethylepipodophyllotoxin) is a natural lignin, which is used in chemotherapy as an aglycon of etoposide. 4′-d-α-DMEP is a novel biological derivative of 4′-d-β-DMEP reported by Jia et al. (2020), which has a higher antitumor activity.

E-ring modifications have only actually focused on enhancing E-ring’s involvement in the cytotoxic mechanism of the compound. With an increased access to the compounds’ physicochemical behavior, a variety of exciting derivatives with successful clinical application have been developed, such as those shown in Figure 7.

4. Plant Sources of Podophyllotoxin

A variety of plant species belonging to approximately over 60 vascular families have been reported as viable sources of podophyllotoxin, which includes genera other than the genus Podophyllum, such as Diphylleia and Dysosma (beriberidaceae), Haplophyllum (Rutaceae), Thuja, Jeffersonia, Anthriscus (Apiaceae), Callitris and Thujopsis (Cupresceae), Hernandia (Hernandiaceae), Nepeta and Thymus (Labiaceae), Catharanthus (Apocynaceae), Teucrium, Hyptis (Verbenaceae), Commiphora (Burseraceae), Polygala (Polygalaceae), Linun (Linaceae), Juniperus and Cassia (Fabaceae). Podophyllotoxin is found accumulated mostly in the roots and rhizomes of these plants but have also been detected in their stems, roots, seeds, fruits, leaves, woody parts and, in some cases, from the associated endophytic microorganisms. However, Podophyllum hexandrum Royle has been reported to contain higher amounts of podophyllotoxin (4.3%) compared to other podophyllotoxin producing plant species. The various podophyllotoxin producing plant species have been tabulated below (Table 1).

5. Biosynthesis of Plant Derived Podophyllotoxin

The understanding of plant pathways is comparatively absolute to the microbial pathways characterized to date. Plant genes that are involved the biosynthetic pathways of various plant-derived clinical drugs remain obscure, hence preventing the transfer of which to heterologous hosts for industrial production. The complete biosynthetic pathway (Figure 8) for podophyllotoxin was elucidated only recently in 2015, allowing more facile access to its natural and processed, clinically significant derivatives—otherwise difficult to synthesize on an industrial scale.

6. Microbial Sources of Podophyllotoxin

Biotechnological procedures for podophyllotoxin production were introduced as a means to overcome its large scale production challenges, which includes the extinction of various podophyllotoxin-plant sources, slow growth of plant sources, exacting constructs and low yields. Micro-organisms, however, demonstrate an enormity of biodiversity, which overdo those of plants. Fungal sources, for instance, have rendered to be a much fruitful alternative to somatic embryogenesis, tissue culturing or macropropagation techniques. The main fungal sources used for industrial podophyllotoxin production are; Trametes hirsuta, Fusarium oxysporum, Fungus Alternaria, Mucor fragilis, Fusarium solani, Trametes histuria, Sebacina vermifera, Phialocephala fortinii and Aspergillus fumigatus. The endophytic sources of podophyllotoxin are also tabulated below Table 2 describes the process of podophyllotoxin production from Fusarium oxysporum, which lives on Juniperus recurva. The outcome suggests F. oxysporum to be a promising contender for industrial podophyllotoxin production. In 2009, the specie Juniperus communis L. Horstmann was also found to produce deoxypodophyllotoxin, which shared remarkable structural relativity to the lignan of podophyllotoxin. No bacterial sources of podophyllotoxin have yet been identified.

7. Parametric Analysis of Podophyllotoxin Biosynthesis

Studies report five major parameters, which influence the biosynthesis of podophyllotoxin; these include luminosity, chilling units/hours, macro- and micro-nutrients and soil’s pH and nutrient availability. Any fluctuation in the strength of which can result in altered podophyllotoxin yields. In the presence of red-light, for instance, increased the overall product formation in comparison to light of other wavelengths; likewise, chilling units set at 4 °C were reported to have caused a 5-folds increase in product yield. The variation in concentrations of macro- and micro-nutrients such as glucose, nitrogen, NO3−, PO43−, Na+, Fe2+, Mn2+, etc., has shown similar correlation with podophyllotoxin production. Moreover, the acidity or alkalinity levels of the soil in cases for podophyllotoxin producing plants also demonstrate yield modifications. These parameters are tabulated and discussed below Table 3.

8. Pharmacological Significance of Podophyllotoxin and Its Derivatives

Podophyllotoxin and its derivatives possess a wide-spectrum of pharmacological potential. The achievability of broad chemical modifications brings the podophyllotoxin pharmacophore its diverse applicability as a medicinal compound—tabulated in Table 4. Antineoplastic activity is the most outstanding of all its clinical properties. Various studies validate podophyllotoxin derivatives including etopophos, teniposide, etoposide, etoposide phosphate, GL331, NK-611, TOP53 and NPF as anticancer drugs. Many clinical studies have reported the efficacy of these compounds against various forms of cancer including lung cancer, Wilmstumours, diverse types of genital tumors such as carcinoma verrucosus and for non-Hodgkin lymphoma, multiform glioblastoma lymphoma and nonlymphocytic leukemia. Podophyllotoxin has also shown activity against various (multi) drug resistant tumor cells. As an example, Hu and coworkers presented a 4-β-anilino-podophyllotoxin derivative as a potential anticancer drug against the KB/VCR cells in both conditions; in vivo and in vitro. For the development of new anticancer drugs, podophyllotoxin containing analogues are of prime focus in recent studies. Ming et al. explained that an endophytic fungus named as Dysosma versipellis has both anticancer and antimicrobial properties. The aqueous extract of Podophyllum peltatum fractionated by reverse-phase chromatography was observingly the most active component that was found to cause the inhibition in the replication process of herpes simplex type 1 virus and measles.

Moreover, picropodophyllotoxin, deoxypodophyllotoxin and peltatins are also determined as useful antiviral compounds. Activity against Sindbis and cytomegalovirus has also been recorded. They either decrease the capacity of the infected cell to release virus or restrain these viruses in the replication cycle at an essential early stage, following the virus absorption into cells. Not only this, podophyllotoxin can also be used for treating Condyloma acuminatum that is usually caused by HPV (papilloma virus) and for treating other perianal and venereal warts. With a goal to achieve better therapeutic effectiveness, cocktail therapies are currently in use with other registered chemotherapeutic agents, combined with additional techniques that are beneficial in fighting against cancer and other viral infections. Podophyllotoxins with interferon therapy has shown greater effectivity against genital human infections, combination with cisplatin, on the other hand, is useful for treating neuroblastomas. Recently a study reports the study progression of etoposide in phase II clinical trials (ClinicalTrials NTC04356690) as a redeveloped drug to treat COVID-19 patients suffering with cytokine storm complication. Similarly, in recent years podophyllotoxin derivatives have shown some interesting insecticidal activities against the larvae of Brontispa longissima and Mythimna separata. Furthermore, derivatives are also being synthesized and used for the treatment of malaria and psoriasis. Podophyllotoxins also hold dermatological significance and prove to be potential therapeutic agents for psoriasis vulgaris. Podophyllotoxin exhibited considerable ichthyotoxic activity and phyto growth inhibitory activities, even though the effects were weaker as compared to deoxy podophyllotoxin, in all cases observed.

Besides the major antiviral and anticancer activities, podophyllotoxin and its derived compounds have also exhibited some further interesting activities such as anti-trypanosomal activity, antimelanocortin-4 receptor (MC4R) activity, antioxidative activity, immunosuppressive, antioxidative, antispasmogenic, hypolipidemic, emetic, laxative and anti-inflammatory activity. Moreover, during the last century, many trials were carried out in an attempt to cure diseases such as syphilis, cough, gonorrhea, dropsy, gout, psoriasis, tuberculosis, tumor, menstrual disorders and venereal warts by using podophyllotoxins. According to Hartwell et al. (1951), podophyllotoxin is particularly abundant in the genus Podophyllum that has been utilized since ancient times as bothanthelminthic and cathartic agents, for medicinal purposes. Podophyllotoxin is demonstrated as a promising and relatively safe drug, for treating genital warts and is also an active ingredient of registered wartec ointments and condylox liquids.

9. Patents

In the past decade, numerous attempts have been globally to produce derivatives or compositions of podophyllotoxins in order to overcome their natural dose-limiting toxicity, poor biodistribution and low aqueous solubility. These inventions have found extensive application for effective chemotherapeutic purposes. These inventions have succeeded at demonstrating sufficient activity and can considerably contribute to future studies, some of these new derivatives are tabulated below (Table 5).

The great interest of institutional researchers and pharmaceutical companies is also validated by a surge in number of patents protecting various inventions involving podophyllotoxin. Searching the term “podophyllotoxin” gave 93,446 results in the Google patent database while 26,582 in the Patent Lens database with the first patent application filed in 1967-12-06 and granted in 1970-08-18. When “podophyllotoxin” is used as keywords for the the patents and/or patent applications annual filed (Figure 9), key applicant companies (Figure 10), key inventors (Figure 11), and key owners based in US (Figure 12)

10. Conclusions

Novel approaches towards structure optimization and the finding of alternative sources can help unravel less toxic, more efficient and easy to yield podophyllotoxin and its derivatives. Being known for decades as the main bioactive compound in various traditional medicinal formulas, these compounds were later approved for clinical use against a number of health conditions. In the recent pandemic, various known drugs were repurposed against the novel coronavirus strain 2019. Amongst this struggle of trial and error, etoposide—a podophyllotoxin derivative well cited for its antineoplastic activity—has also been redeveloped to manage cytokine storm complication in COVID-19 patients. This finding opens new potential for podophyllotoxin, its derivatives and its congeners to be explored. For as the growing demand for podophyllotoxin is increasing, plant sources are proving to be an unreliable option for the future, this explains the exigency of utilizing microbial biotransformation as a considerable approach along with the need of devoted effort towards rationally designing the new generation of the group of podophyllotoxin-derived compounds.

Figures12

From PubMed Central, U.S. National Library of Medicine.

The sequential discovery of podophyllotoxin-group of drugs. FDA approved anticancer drugs etoposide, teniposide and etopophos were derived from the parent compound podophyllotoxin, which was originally extracted from mayapple plant as a curative for

Figure 1

Full legend

The sequential discovery of podophyllotoxin-group of drugs. FDA approved anticancer drugs etoposide, teniposide and etopophos were derived from the parent compound podophyllotoxin, which was originally extracted from mayapple plant as a curative for various diseases. As the side-effects for podophyllotoxin and its primary derivatives became evident, less toxic derivatives such as TOP-53, NK611, GL-331, azatoxin and various others were designed and synthesized.

Open Figure 1 full size (opens in a new tab)
Structural representation of podophyllotoxin. The structure is constituted of 4 aromatic rings A, B, C and D arranged in an almost planar system whereas ring E is attached quasi-axially at C4 of ring C.

Figure 2

Full legend

Structural representation of podophyllotoxin. The structure is constituted of 4 aromatic rings A, B, C and D arranged in an almost planar system whereas ring E is attached quasi-axially at C4 of ring C.

Open Figure 2 full size (opens in a new tab)
Podophyllotoxin derivatives produced by selective cleavage of ring A through Schreier’s method and the modified-Schreier method. These ring-A-open compounds, however, appeared biologically less active than podophyllotoxin itself.

Figure 3

Full legend

Podophyllotoxin derivatives produced by selective cleavage of ring A through Schreier’s method and the modified-Schreier method. These ring-A-open compounds, however, appeared biologically less active than podophyllotoxin itself.

Open Figure 3 full size (opens in a new tab)
The significance of ring A for biological functionality of podophyllotoxin and its derivatives introduced three crucially significant domains in the parent pharmacophore model. Modifying these domains provided a number of new derivatives as shown (Co

Figure 4

Full legend

The significance of ring A for biological functionality of podophyllotoxin and its derivatives introduced three crucially significant domains in the parent pharmacophore model. Modifying these domains provided a number of new derivatives as shown (Compound XX1–XXVI). These compounds show distinct mechanism of actions in comparison to the previously discovered podophyllotoxin derivatives.

Open Figure 4 full size (opens in a new tab)
Structures of alpha-peltatin and beta-peltatin. These two B-ring modified podophyllotoxin derivatives are known to exhibit significant antiviral and antitumor activities. The B-ring modified pharmacophore was identified from these compounds and was t

Figure 5

Full legend

Structures of alpha-peltatin and beta-peltatin. These two B-ring modified podophyllotoxin derivatives are known to exhibit significant antiviral and antitumor activities. The B-ring modified pharmacophore was identified from these compounds and was taken further to synthesize more derivatives—as shown bracketed—none of which elicited any clinical efficacy.

Open Figure 5 full size (opens in a new tab)
A series of delactonized D-ring derivatives have remained the focus of many studies. An ethyl hydrazide derivative, drawn here, was reportedly the only D-ring modified compound, which showed clinical efficacy, but was discontinued after occurrence of

Figure 6

Full legend

A series of delactonized D-ring derivatives have remained the focus of many studies. An ethyl hydrazide derivative, drawn here, was reportedly the only D-ring modified compound, which showed clinical efficacy, but was discontinued after occurrence of various cases of severe side-effects related to its use.

Open Figure 6 full size (opens in a new tab)
Show all 12 figures
The figure shows structural illustrations of E-ring modified derivatives much of which have proved to be clinically significant.

Figure 7

Full legend

The figure shows structural illustrations of E-ring modified derivatives much of which have proved to be clinically significant.

Open Figure 7 full size (opens in a new tab)
The production of podophyllotoxin in plants takes place in 33 steps where coniferyl alcohol acts as the precursor. The pathway is called phenylpropanoid pathway. In the early steps of podophyllotoxin biosynthesis coniferyl alcohol in formed in nine s

Figure 8

Full legend

The production of podophyllotoxin in plants takes place in 33 steps where coniferyl alcohol acts as the precursor. The pathway is called phenylpropanoid pathway. In the early steps of podophyllotoxin biosynthesis coniferyl alcohol in formed in nine steps from phenylalanine. Coniferyl alcohol then undergoes a site-selective and unusual enantio-dimerization to form (+)-pinoresinol. Pinoresinol is then reduced to (−)-secoisolariciresinol, which is catalyzed by a dehydrogenase to (−)-matairesinol. The next intermediate formed is (−)-pluviatolide, which is methylated to (−)-5′-desmethoxy-yatein that is converted to the yatein. Yatein is the intermediate that gets converted to the end product; podophyllotoxin [109].

Open Figure 8 full size (opens in a new tab)
Year wise patent publications filed on podophyllotoxin.

Figure 9

Full legend

Year wise patent publications filed on podophyllotoxin.

Open Figure 9 full size (opens in a new tab)
Key patent filing companies on podophyllotoxin.

Figure 10

Full legend

Key patent filing companies on podophyllotoxin.

Open Figure 10 full size (opens in a new tab)
Key inventors in the podophyllotoxin field.

Figure 11

Full legend

Key inventors in the podophyllotoxin field.

Open Figure 11 full size (opens in a new tab)
Top US owners of patents related to podophyllotoxin.

Figure 12

Full legend

Top US owners of patents related to podophyllotoxin.

Open Figure 12 full size (opens in a new tab)

References161

  1. 1.

    Cane C., Moracs R.M. Podophyllotoxin. Phytochemistry. 2000;54:115-120.

    Not in our library10.1016/s0031-9422(00)00094-7 (opens in a new tab)

  2. 2.

    Gordaliza M., Garcia P.A., Miguel del Corral J.M. Podophyllotoxin: Distribution, sources, applications, and new cytotoxic derivatives. Toxicon. 2004;44:441-459.

    Not in our library10.1016/j.toxicon.2004.05.008 (opens in a new tab)

  3. 3.

    Hartwell J.L., Schrecker A.W. Components of Podophyllin. V. The Constitution of Podophyllotoxin. J. Am. Chem. Soc. 1951;73:2909-2916.

    Not in our library10.1021/ja01150a143 (opens in a new tab)

  4. 4.

    Ayres D.C., Loike J.D. Lignans, Chemical, Biological and Clinical Properties. 1990.

    Not in our library

  5. 5.

    King J. Discovery of Podophyllin. Coll. J. M. Sci. 1875;2:557-559.

    Not in our library

  6. 6.

    Liu C.J., Hou S.S. Current Research Status of Podophyllotoxin Lignans. Nat. Prod. Res. Dev. 1997;9:81-89.

    Not in our library

  7. 7.

    Chen Y.H. A Study of the Resources of Chinese Podophyllin Plants. Acta Pharm. Sin. 1979;14:101-107.

    Not in our library

  8. 8.

    Yang X.Z., Shao H., Zhang L.Q., Zhou C., Xuan Q., Yang C.Y. Present Situation of Studies on Resources of Podophyllotoxin. Chin. Tradit. Herb. Drugs. 2001;32:1042-1044.

    Not in our library

  9. 9.

    Liu H.J., Xu Y., Su G.Q., Li C.Y., Wang L., Liu Y.J. Research Progress in Sinopodophyllum emodi. Chin. Tradit. Herb. Drugs. 2004;35:98-100.

    Not in our library

  10. 10.

    Macrae D.W., Towers N.G.H. Biological Activity of Lignans. Phytochemistry. 1984;23:1207-1220.

    Not in our library10.1016/s0031-9422(00)80428-8 (opens in a new tab)

  11. 11.

    Bohlin L., Rosen B. Podophyllotoxin derivatives: Drug discovery and development. Drug Discov. Today. 1996;1:343-351.

    Not in our library10.1016/1359-6446(96)10028-3 (opens in a new tab)

  12. 12.

    Cragg G.M., Kingston D.G. Anticancer Agents from Natural Products. 2011;97.

    Not in our library

  13. 13.

    Podwyssotzki V. The active constituents of podophyllotoxin. Pharm. J. Trans. 1881;12:217-218.

    Not in our library

  14. 14.

    Podwyssotzki V. On the active constituents of podophyllin. Am. J. Pharm. 1882;12:102-115.

    Not in our library

  15. 15.

    Podwyssotzki V. Pharmakologische Studien uber podophyllum peltatum. NaunynSchmied Arch. Exp. Path. Phar. 1884;13:29-52.

    Not in our library10.1007/bf01833268 (opens in a new tab)

  16. 16.

    Species Plantrum. 1753;505.

    Not in our library

  17. 17.

    Yu X., Che Z.P., Xu H. Recent Advances in the Chemistry and Biology of Podophyllotoxins. Chem. Eur. J. 2016;10:1002-1006.

    Not in our library10.1002/chem.201602472 (opens in a new tab)

  18. 18.

    Stoll A., Renz J., Wartburg A.V. The isolation of podophyllotoxin glucoside. J. Am. Chem. Soc. 1954;76:3103-3104.

    Not in our library10.1021/ja01640a094 (opens in a new tab)

  19. 19.

    Stoll A., von Wartburg A., Angliker E., Renz J. The isolation of 4′- Demethylpodophyllotoxin glucoside from rhizomes podophyllum emodi wall. J. Am. Chem. Soc. 1954;76:5004-5005.

    Not in our library10.1021/ja01648a086 (opens in a new tab)

  20. 20.

    Emmenggger H., Stahelin H., Rutschmann J., von Wartburg A. Chemistry and Pharmacology of podophyllum glucosides and derivatives. I. Arzneim. 1961;11:327-333.

    Not in our library

  21. 21.

    Kuhn M., von Wartburg A. Mitosis-inhibiting substances. XXI. Synthesis of epipodophyllotoxin b-D-glucopyranoside. Helv. Chim. Acta. 1968;51:1631-1641.

    Not in our library10.1002/hlca.19680510719 (opens in a new tab)

  22. 22.

    Kuhn M., von Wartburg A. Mitosis-inhibiting substances. glycosidation process.II. Glycosides of 4″-demethylepipodo-phyllotoxin. Helv. Chim. Acta. 1969;52:948-955.

    Not in our library10.1002/hlca.19690520411 (opens in a new tab)

  23. 23.

    Keller-Juslen C., Kuhn M., Von Wartburg A., Staehelin H. Synthesis and antimitotic activity of glycosidic lignan derivatives related to podophyllotoxin. J. Med. Chem. 1971;14:936-940.

    Not in our library10.1021/jm00292a012 (opens in a new tab)

  24. 24.

    Joel S. The clinical pharmacology of etoposide. An update. Cancer Treat. Rev. 1996;22:179-221.

    Not in our library10.1016/s0305-7372(96)90002-x (opens in a new tab)

  25. 25.

    Stahelin H.F., von Wartburg A. The Chemical and Biological Route from Podophyllotoxin Glucoside to Etoposide: Ninth Cain Memorial Award Lecture. Cancer Res. 1991;51:5-15.

    Not in our library

  26. 26.

    Ardalani H., Avan A., Ghayour-Mobarhan M. Podophyllotoxin: A novel potential natural anticancer agent. Avicenna J. Phytomed. 2017;7:285-294.

    Not in our library

  27. 27.

    Mross K., Huttmann A., Herbst K., Hanauske A.R., Schilling T., Manegold C., Burk K., Hossfeld D.K. Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611 A study by the AIO groups PHASE-I and APOH. Cancer Chemother. Pharmacol. 1996;38:217-224.

    Not in our library10.1007/s002800050474 (opens in a new tab)

  28. 28.

    Huang T.S., Lee C.C., Chao Y., Shu C.H., Chen L.T., Chen L.L., Chen M.H., Yuan C.C., Whang-Peng J. A novel podophyllotoxin-derived compound GL331 is more potent than its congener VP-16 in killing refractory cancer cells. Pharm. Res. 1999;16:997-1002.

    Not in our library10.1023/a:1018971313256 (opens in a new tab)

  29. 29.

    Lee C.C., Huang T.S. A novel topoisomerase GL331 preferentially induces DNA cleavage at (C/G)T sites and can cause telomere DNA damage. Pharm. Res. 2001;18:846-851.

    Not in our library10.1023/a:1011048831698 (opens in a new tab)

  30. 30.

    Solary E., Leteurtre F., Paull K.D., Scudiero D., Hamel E., Pommier Y. Dual inhibition of topoisomerase II and tubulin polymerization by azatoxin, a novel cytotoxic agent. Biochem. Pharm. 1993;45:2449-2456.

    Not in our library10.1016/0006-2952(93)90226-m (opens in a new tab)

  31. 31.

    Arora R. Medicinal Plant Biotechnology. 2010.

    Not in our library

  32. 32.

    You Y. Podophyllotoxin derivatives: Current synthetic approaches for new anticancer agents. J. Curr. Pharm. Des. 2005;11:1695-1717.

    Not in our library10.2174/1381612053764724 (opens in a new tab)

  33. 33.

    Bromberg L. Polyether-modified poly (acrylic acid): Synthesis and applications. Ind. Eng. Chem. Res. 1998;37:4267-4274.

    Not in our library10.1021/ie980358s (opens in a new tab)

  34. 34.

    Von-Schreier E. Partial synthese der 6, 7-Dimethoxy-Analogen von Podophyllotoxin, Epi-, Neo-, und Desoxy-podophyllotoxin. Helv. Chim. Acta. 1964;47:1529-1554.

    Not in our library10.1002/hlca.19640470616 (opens in a new tab)

  35. 35.

    Wang Z.Q., Hu H., Chen H.X., Cheng Y.C., Lee K.H. New 4 beta-substituted aniline derivatives of 6,7-O,O-demethylene-4’-O-demethylpodophyllotoxin and related compounds as potent inhibitors of human DNA topoisomerase II. J. Med. Chem. 1992;35:871-877.

    Not in our library10.1021/jm00083a010 (opens in a new tab)

  36. 36.

    Cho S.J., Kashiwada Y., Bastow K.F., Cheng Y.C., Lee K.H. Podophenazine, 2″,3″-Dichloropo-dophenazine, Benzopodophenazine, and Their 4b-p-Nitroaniline Derivatives as Novel DNA Topoisomerase II Inhibitors. J. Med. Chem. 1996;39:1396-1402.

    Not in our library10.1021/jm950548u (opens in a new tab)

  37. 37.

    Cho S.J., Tropsha A., Suffness M., Cheng Y.C., Lee K.H. Three-Dimensional Quantitative Structure-Activity Relationship Study of 4’-O-Demethyl-epipodophyllotoxin Analogs Using the Modified CoMFA/q2 -GRS Approach. J. Med. Chem. 1996;39:1383-1395.

    Not in our library10.1021/jm9503052 (opens in a new tab)

  38. 38.

    Hartwell J.L. α-Peltatin, a new compound isolated from podophyllum peltatum. J. Am. Chem. Soc. 1947;69:2918.

    Not in our library10.1021/ja01203a515 (opens in a new tab)

  39. 39.

    Stoll A., von Wartburg A., Renz J. The isolation of a-peltatin glucoside from the rhizomes of Podophyllum peltatum L. J. Am. Chem. Soc. 1955;77:1710-1711.

    Not in our library10.1021/ja01611a110 (opens in a new tab)

  40. 40.

    Nagar N., Jat R.K., Saharan R., Verma S., Sharma D., Bansal K. Podophyllotoxin and their Glycosidic derivatives. Pharmacophore. 2011;2:87-97.

    Not in our library

  41. 41.

    Bedows E., Hatfield G.M. An Investigation of the Antiviral Activity of Podophyllum peltatum. J. Nat. Prod. 1982;45:725-729.

    Not in our library10.1021/np50024a015 (opens in a new tab)

  42. 42.

    Thurston L.S., Irie H., Tani S., Han F.S., Liu Z.C., Cheng Y.C., Lee K.H. Inhibition of human DNA topoisomerase II by podophyllotoxin and alpha-peltatin analogs. J. Med. Chem. 1986;29:1547-1550.

    Not in our library10.1021/jm00158a042 (opens in a new tab)

  43. 43.

    Thurston L.S., Imakura Y., Haruna M., Li D.H., Liu Z.C., Liu S.Y., Cheng Y.C., Lee K.H. Inhibition of human DNA topoisomerase II by cytotoxic ether and ester derivatives of podophyllotoxin and alpha-peltatin. J. Med. Chem. 1989;32:604-608.

    Not in our library10.1021/jm00123a016 (opens in a new tab)

  44. 44.

    Beers S.A., Imakura Y., Dai H.J., Li D.H., Cheng Y.C., Lee K.H. Synthetic Ring C Aromatized Podophyllotoxin Analogues as Potential Inhibitors of Human DNA Topoisomerase II. J. Nat. Prod. 1988;51:901-905.

    Not in our library10.1021/np50059a014 (opens in a new tab)

  45. 45.

    Canjanamurthy K., Lokanatharai M. Synthesis of Podophyllotoxin & related analogues: Part II-Synthesis of ß-apopicrophyllin analogues with modified Hydroaromatic ring-B. Indian J. Chem. 1985;24:505-508.

    Not in our library

  46. 46.

    Canjanamurthy K., Lokanatharai M. Synthesis of Podophyllotoxin & related analogues: Part III-Synthesis of ß-apopicrophyllin analogues with modified lactone ring. Indian J. Chem. 1987;26:131-135.

    Not in our library

  47. 47.

    He Y., Ma W.Y., Zhang C.N. The effects of unsaturated factors on ring C to chemical Properties of podophyllotoxin analogues. J. Chin. Pharm. Sci. 2001;10:81-84.

    Not in our library

  48. 48.

    Kamal A., Reddy S.T., Polepalli S., Shalini N., Reddy V.G., Subba Rao A.V., Shankaraiah N. Synthesis and biological evaluation of podophyllotoxin congeners as tubulin polymerization inhibitors. Bioorg. Med. Chem. 2014;22:5466-5475.

    Not in our library10.1016/j.bmc.2014.07.031 (opens in a new tab)

  49. 49.

    Guo H.Z., Guo D.A., Fei X.Y., Cui Y.J., Zheng J.H. Biotransformation of podophyllotoxin to picropodophyllin by microbes. J. Asian Nat. Prod. Res. 1998;1:99-102.

    Not in our library10.1080/10286029808039850 (opens in a new tab)

  50. 50.

    Larsson M.A. Cyclolignans as inhibitors of the insulin-like growth factor-I receptor. Cancer Res. 2007;67:2899.

    Not in our library10.1158/0008-5472.can-06-3659 (opens in a new tab)

  51. 51.

    Vasilcanu R., Vasilcanu D., Rosengren L., Natalishvili N., Sehat B., Yin S., Girnita A., Axelson M., Girnita L., Larsson O. Picropodophyllin induces down regulation of the insulin-like growth factor 1 receptor: Potential mechanistic involvement of Mdm2 and beta-arrestin. Oncogene. 2008;27:1629-1638.

    Not in our library10.1038/sj.onc.1210797 (opens in a new tab)

  52. 52.

    Walter J., Gensler C.D., Murthy M.H.T. Non-enolizable podophyllotoxin derivatives. J. Med. Chem. 1977;20:635-644.

    Not in our library10.1021/jm00215a004 (opens in a new tab)

  53. 53.

    Glinski M.B., Freed J.C., Durst T. Preparation of 2-substituted podophyllotoxin derivatives. J. Org. Chem. 1987;52:2749-2753.

    Not in our library10.1021/jo00389a020 (opens in a new tab)

  54. 54.

    Van-Vliet D.S., Lee K.H. A high yield preparation of 2-fluoropodophyllotoxin. Tetrahedron. Lett. 1999;40:2259-2262.

    Not in our library10.1016/s0040-4039(99)00220-8 (opens in a new tab)

  55. 55.

    Van-Vliet D.S., Tachibana Y., Bastow K.F., Huang E.S., Lee K.H. Design, Synthesis, and Biological Testing of 4b-Anilino-2-fluoro-4’-demethylpodophyllo-toxin Analogues as Cytotoxic and Antiviral Agents. J. Med. Chem. 2001;44:1422-1428.

    Not in our library10.1021/jm000377f (opens in a new tab)

  56. 56.

    Laatsch H., Ernst B.P., Noltemeyer M. Synthesis of Sterically Fixed Podophyllotoxin. Liebigs Ann. 1996;1996:731-737.

    Not in our library10.1002/jlac.199619960514 (opens in a new tab)

  57. 57.

    Zhou X.M., Lee K.J.H., Cheng J., Wu S.S., Chen H.X., Guo X., Cheng Y.C., Lee K.H. New gamma-lactone ring-modified arylamino etoposide analogs as inhibitors of human DNA topoisomerase II. J. Med. Chem. 1994;37:287-292.

    Not in our library10.1021/jm00028a012 (opens in a new tab)

  58. 58.

    Gordaliza M., Faircloth G.T., Castro M.A., Miguel del Corral J.M., Lopez-Vazquez M.L., Feliciano S.A. Immunosuppressive cyclolignans. J. Med. Chem. 1996;39:2865-2868.

    Not in our library10.1021/jm960023h (opens in a new tab)

  59. 59.

    Subrahmanyam D., Renuka B., Laxmana-Rao C.V., Sagar S.P., Deevi D.S., Babu J.M., Vyas K. Novel D-ring analogues of podophyllotoxin as potent anti-cancer agents. Bioorg. Med. Chem. Lett. 1998;8:1391-1396.

    Not in our library10.1016/s0960-894x(98)00232-7 (opens in a new tab)

  60. 60.

    Subrahmanyam D., Renuka B., Sunil K.G., Vandana V., Deevi D.S. 9-Deoxopodophyllotoxin derivatives as anti-cancer agents. Bioorg. Med. Chem. Lett. 1999;9:2131-2134.

    Not in our library10.1016/s0960-894x(99)00347-9 (opens in a new tab)

  61. 61.

    Gaspar N., Occean B.V., Pacquement H., Bompas E., Bouvier C., Brisse H.J., Castex M.P., Cheurfa N., Corradini N., Delaye J., et al. Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study. Eur. J. Cancer. 2018;88:57-66.

    Not in our library10.1016/j.ejca.2017.09.036 (opens in a new tab)

  62. 62.

    Lau W., Sattely E.S. Six enzymes from mayapple that complete the biosynthetic pathway to the etoposide aglycone. Science. 2015;349:1224-1228.

    Not in our library10.1126/science.aac7202 (opens in a new tab)

  63. 63.

    Jia K.Z., Zhan X., Li H.M., Shen Y., Qi Q., Zhang Y., Li Y.Z., Tang Y.J. A novel podophyllotoxin derivative with higher anti-tumor activity produced via 4′-demethylepipodophyllotoxin biotransformation by Penicillium purpurogenum. Process Biochem. 2020;96:220-227.

    Not in our library10.1016/j.procbio.2020.05.006 (opens in a new tab)

  64. 64.

    Liu Y.Q., Yang L., Tian X. Podophyllotoxin: Current Perspectives. Curr. Bioact. Compd. 2007;3:37-66.

    Not in our library

  65. 65.

    Hernandez A.P., Diez P., Garcia P.A., Perez-Andres M., Ortega P., Jambriana P.G., Diez D., Castro M.A., Fuentes M. A Novel Cytotoxic Conjugate Derived from the Natural Product Podophyllotoxin as a Direct-Target Protein Dual Inhibitor. Molecules. 2020;25:4258.

    Not in our library10.3390/molecules25184258 (opens in a new tab)

  66. 66.

    Kumar P., Pal T., Sharma N., Kumar V., Sood H., Chauhan R.S. Expression analysis of biosynthetic pathway genes vis-à-vis podophyllotoxin content in Podophyllum hexandrum Royle. Protoplasma. 2015;252:1253-1262.

    Not in our library10.1007/s00709-015-0757-x (opens in a new tab)

  67. 67.

    Rollinger J.M., Zidorn C., Dobner M.J., Ellmerer E.P., Stuppner H. Lignans, phenylpropanoids and polyacetylenes from Chaerophyllum aureum L. (Apiaceae). Z. Nat. C. 2003;58:553-557.

    Not in our library10.1515/znc-2003-7-818 (opens in a new tab)

  68. 68.

    Al-Juaid S.S., Abdel-Mogib M. A novel podophyllotoxin lignan from Justicia heterocarpa. Chem. Pharm. Bull. 2004;52:507-509.

    Not in our library10.1248/cpb.52.507 (opens in a new tab)

  69. 69.

    Yu P.Z., Wang L.P., Chen Z.N. A new podophyllotoxin-type lignan from Dysosma versipellis var. tomentosa. J. Nat. Prod. 1991;54:1422-1424.

    Not in our library10.1021/np50077a034 (opens in a new tab)

  70. 70.

    Bedir E., Khan I., Moraes R.M., Janick J., Whipkey A. Bioprospecting for Podophyllotoxin. Trends in New Crops and New Uses. 2002;545-549.

    Not in our library

  71. 71.

    Gohar U.F., Iqbal I., Shah Z., Mukhtar H., Zia-Ul-Haq M., Zia-Ul-Haq M., Bin-Jumah M.N., Alothamn S.I., Henidi H.A. COVID-19: Recent Developments in Therapeutic Approaches. Alternative Medicine Interventions for COVID-19. 2021;249-274.

    Not in our library

  72. 72.

    Liang Z., Zhang J., Xuan Z., Li J., Xiaoqian Z., Zhao C. Endophytic fungus from Sinopodophyllum emodi (Wall.) ying that produces Podophyllotoxin. J. Chromatogr. Sci. 2016;54:175-178.

    Not in our library10.1093/chromsci/bmv124 (opens in a new tab)

  73. 73.

    Karuppaiya P., Tsay H.S. Enhanced production of podophyllotoxin, kaempferol, and quercetin from callus culture of Dysosma pleiantha (Hance) woodson: An endangered medicinal plant. Biotech. Appl. Biochem. 2019;67:95-104.

    Not in our library10.1002/bab.1810 (opens in a new tab)

  74. 74.

    Bianchi E., Caldwell M.E., Cole J.R. Antitumor agents from Bursera microphylla (Burseraceae) I. Isolation and characterization of deoxypodophyllotoxin. J. Pharm. Sci. 1968;57:696-697.

    Not in our library10.1002/jps.2600570436 (opens in a new tab)

  75. 75.

    Provan G.J., Waterman P.G. Picropolygamain: A New Lignan from Commiphora incisa Resin1. Planta Med. 1985;51:271-272.

    Not in our library10.1055/s-2007-969479 (opens in a new tab)

  76. 76.

    Wickramaratne D.B.M., Mar W., Chai H., Castillo J.J., Farnsworth N.R., Soejarto D.D., Cordell G.A., Pezzuto J.M., Kinghorn A.D. Cytotoxic constituents of Bursera permollis. Planta Med. 1995;61:80-81.

    Not in our library10.1055/s-2006-958008 (opens in a new tab)

  77. 77.

    Jutiviboonsuk A., Zhang H., Tan G.T., Ma C., Van-Hung N., Cuong N.M., Bunyapraphatsara N., Soejarto D.D., Fong H.H. Bioactive constituents from roots of Bursera tonkinensis. Phytochemistry. 2005;66:2745-2751.

    Not in our library10.1016/j.phytochem.2005.09.025 (opens in a new tab)

  78. 78.

    Velazquez-Jimenez R., Torres-Valencia J.M., Cerda-García-Rojas C.M., Hernandez-Hernández J.D., Roman-Marín L.U., Manríquez-Torres J.J., Gomez-Hurtado M.A., Valdez-Calderon A., Motilva V., García-Maurino S., et al. Absolute configuration of podophyllotoxin related lignans from Bursera fagaroides using vibrational circular dichroism. Phytochemistry. 2011;72:2237-2243.

    Not in our library10.1016/j.phytochem.2011.07.017 (opens in a new tab)

  79. 79.

    Feliciano A.S., Medarde M., Lopez J.L., Puebla P., Miguel del Corral J.M., Barrer A.F. Lignans from Juniperus thurifera. Phytochemistry. 1989;28:2863-2866.

    Not in our library10.1016/s0031-9422(00)98111-1 (opens in a new tab)

  80. 80.

    Aynehchi Y. Desoxypodophyllotoxin, the cytotoxic principle of Callitris columellaris F. Muell. J. Pharm. Sci. 1971;60:121-122.

    Not in our library10.1002/jps.2600600125 (opens in a new tab)

  81. 81.

    Van U.W., Pras N., Vossebeld E.M., Mol J.N., Malingre T.M. Production of 5-methoxypodophyllotoxin in cell suspension cultures of Linum flavum L. Tissue Organ Cult. 1990;20:81-87.

    Not in our library

  82. 82.

    Kier L.B., Fitzgerald D.B., Burgett S. Isolation of podophyllotoxin from Callitrus drummondii. J. Pharm. Sci. 1963;52:502-503.

    Not in our library10.1002/jps.2600520526 (opens in a new tab)

  83. 83.

    Hartwell J.L., Johnson J.M., Fitzgerald D.B., Belkin M. Podophyllotoxin from Juniperus species; savinin. JACS. 1953;75:235-236.

    Not in our library10.1021/ja01097a511 (opens in a new tab)

  84. 84.

    Muranaka T., Miyata M., Ito K., Tachibana S. Production of podophyllotoxin in Juniperus chinensis callus cultures treated with oligosaccharides and a biogenetic precursor in honour of Professor GH Neil towers 75th birthday. Phytochemistry. 1998;49:491-496.

    Not in our library10.1016/s0031-9422(98)00295-7 (opens in a new tab)

  85. 85.

    Chang L.C., Song L.L., Park E.J., Luyengi L., Lee K.J., Farnsworth N.R., Pezzuto J.M., Kinghorn A.D. Bioactive constituents of Thuja occidentalis. J. Nat. Prod. 2000;63:1235-1238.

    Not in our library10.1021/np0001575 (opens in a new tab)

  86. 86.

    Mikac S., Markulin L., Drouet S., Corbin C., Tungmunnithum D., Kiani R., Kabra A., Abbasi B.H., Renouard S., Bhambra A., et al. Bioproduction of Podophyllotoxin and Related Aryltretralin-Lignans in Hairy Root Cultures of Linum Flavum L. Plant Cell Tissue Differ. Second. Metab. Fundam. Appl. 2021;503-540.

    Not in our library10.1007/978-3-030-11253-0_20-1 (opens in a new tab)

  87. 87.

    Cantrell C.L., Zheljazkov V.D., Osbrink W.L., Castro A., Maddox V., Craker L.E., Astatkie T. Podophyllotoxin and essential oil profile of Juniperus and related species. Ind. Crop. Prod. 2013;43:668-676.

    Not in our library10.1016/j.indcrop.2012.07.075 (opens in a new tab)

  88. 88.

    Och M., Och A., Ciesla L., Kubrak T., Pecio L., Stochmal A., Kocki J., Bogucka-Kocka A. Study of cytotoxic activity, podophyllotoxin, and deoxypodophyllotoxin content in selected Juniperus species cultivated in Poland. Pharm. Biol. 2015;53:831-837.

    Not in our library10.3109/13880209.2014.943246 (opens in a new tab)

  89. 89.

    Renouard S., Corbin C., Colas C., Fidel T., Lopez T., Leclerc E.A., Hendrawati O., Falguieres A., Doussot J., Ferroud C., et al. Aerial parts of Callitris species as a rich source of deoxypodophyllotoxin. Ind. Crop. Prod. 2015;63:53-57.

    Not in our library10.1016/j.indcrop.2014.10.055 (opens in a new tab)

  90. 90.

    Wanner J., Jirovetz L., Schmidt E. Callitris intratropica RT Baker & HG Smith as a novel rich source of deoxypodophyllotoxin. Curr. Bioact. Compd. 2015;11:73-77.

    Not in our library

  91. 91.

    Doussot J., Mathieu V., Colas C., Molinie R., Corbin C., Montguillon J., Banuls L.M.Y., Renouard S., Lamblin F., Dupre P., et al. Investigation of the lignan content in extracts from Linum, Callitris and Juniperus species in relation to their in vitro antiproliferative activities. Planta Med. 2017;234:574-581.

    Not in our library10.1055/s-0042-118650 (opens in a new tab)

  92. 92.

    Kasparova M., Martin J., Tu A.L., Spilkov A.J. Production of podophyllotoxin by plant tissue cultures of Juniperus virginiana. Nat. Prod. Commun. 2017;12:101-103.

    Not in our library

  93. 93.

    Broomhead A.J., Dewick P.M. Aryltetralin lignans from Linum flavum and Linum capitatum. Phytochemistry. 1990;29:3839-3844.

    Not in our library10.1016/0031-9422(90)85343-e (opens in a new tab)

  94. 94.

    Smollny T., Wichers H., De Rijk T., Van Zwam A., Shasavari A., Alfermann A.W. Formation of lignans in suspension cultures of Linum album. Planta Med. 1992;58:622-624.

    Not in our library10.1055/s-2006-961624 (opens in a new tab)

  95. 95.

    Kranz K., Petersen M. β-Peltatin 6-O-methyltransferase from suspension cultures of Linum nodiflorum. Phytochemistry. 2003;64:453-458.

    Not in our library10.1016/s0031-9422(03)00196-1 (opens in a new tab)

  96. 96.

    Kartal M., Konuklugil B., Indrayanto G., Alfermann A.W. Comparison of different extraction methods for the determination of podophyllotoxin and 6-methoxypodophyllotoxin in Linum species. J. Pharm. Biomed. Anal. 2004;35:441-447.

    Not in our library10.1016/j.jpba.2004.01.016 (opens in a new tab)

  97. 97.

    Vasilev N., Ionkova I. Lignan accumulation in cell cultures of Linum strictum ssp. strictum L. Acta Pharm. 2004;54:347-351.

    Not in our library

  98. 98.

    Mohagheghzadeh A., Gholami A., Soltani M., Hemmati S., Alfermann W. Linum mucronatum: Organ to organ lignan variations. Z. Nat. C. 2005;60:508-510.

    Not in our library10.1515/znc-2005-5-622 (opens in a new tab)

  99. 99.

    Van Furden B., Humburg A., Fuss E. Influence of methyl jasmonate on podophyllotoxin and 6-methoxypodophyllotoxin accumulation in Linum album cell suspension cultures. Plant Cell Rep. 2005;24:312-317.

    Not in our library10.1007/s00299-005-0954-8 (opens in a new tab)

  100. 100.

    Federolf K., Alfermann A.W., Fuss E. Aryltetralin-lignan formation in two different cell suspension cultures of Linum album: Deoxypodophyllotoxin 6-hydroxylase, a key enzyme for the formation of 6-methoxypodophyllotoxin. Phytochemistry. 2007;68:1397-1406.

    Not in our library10.1016/j.phytochem.2007.02.031 (opens in a new tab)

  101. 101.

    Baldi A., Jain A., Gupta N., Srivastava A.K., Bisaria V.S. Co-culture of arbuscular mycorrhiza-like fungi (Piriformospora indica and Sebacina vermifera) with plant cells of Linum album for enhanced production of podophyllotoxins: A first report. Biotechnol. Lett. 2008;30:1671-1677.

    Not in our library10.1007/s10529-008-9736-z (opens in a new tab)

  102. 102.

    Lautie E., Quintero R., Fliniaux M.A., Villarreal M.L. Selection methodology with scoring system: Application to Mexican plants producing podophyllotoxin related lignans. J. Ethnopharmacol. 2008;120:402-412.

    Not in our library10.1016/j.jep.2008.09.014 (opens in a new tab)

  103. 103.

    Vasilev N., Ebel R., Edrada R.A., Fuss E., Alfermann A.W., Ionkova I., Petrova A., Repplinger M., Schmidt T.J. Metabolic profiling of lignan variability in Linum species of section Syllinum native to Bulgaria. Planta Med. 2008;74:273-280.

    Not in our library10.1055/s-2008-1034298 (opens in a new tab)

  104. 104.

    Samadi A., Jafari M., Nejhad N.M., Hossenian F. Podophyllotoxin and 6-methoxy podophyllotoxin production in hairy root cultures of Liunm mucronatum ssp. mucronatum. Pharmacogn. Mag. 2014;10:154.

    Not in our library10.4103/0973-1296.131027 (opens in a new tab)

  105. 105.

    Sasheva P., Ionkova I. Podophyllotoxin production by cell cultures of Linum thracicum ssp. thracicum Degen elicited with methyl jasmonate and salicylic acid. Comptes Rendus Acad. Bulg. Sci. 2015;68:883-889.

    Not in our library

  106. 106.

    Esfandiari M., Sharifi M., Mohamadyar-Toupkanlou F., Hanaee-Ahwaz H., Yousefzadi M., Jafari A., Hosseinzadeh S., Soleimani M. Optimization of cell/tissue culture of Linum persicum for production of lignans derivatives including Podophyllotoxin. Tissue Organ Cult. 2018;133:51-61.

    Not in our library10.1007/s11240-017-1360-y (opens in a new tab)

  107. 107.

    Lalaleo L., Testillano P., Risueno M.C., Cusido R.M., Palazon J., Alcazar R., Bonfill M. Effect of in vitro morphogenesis on the production of podophyllotoxin derivatives in callus cultures of Linum album. J. Plant Physiol. 2018;228:47-58.

    Not in our library10.1016/j.jplph.2018.05.007 (opens in a new tab)

  108. 108.

    Kamal A., Ali-Hussaini S.M., Rahim A., Riyaz S. Podophyllotoxinderivatives: A patent review (2012–2014). Expert Opin. Ther. Pat. 2015;25:1025-1034.

    Not in our library10.1517/13543776.2015.1051727 (opens in a new tab)

  109. 109.

    Zia-Ul-Haq M., Zia-Ul-Haq M., Dewanjee S., Riaz M. Historical and Introductory Aspects of Carotenoids. Carotenoids: Structure and Function in the Human Body. 2021;1-42.

    Not in our library

  110. 110.

    Puri S.C., Nazir A., Chawla R., Arora R., Riyaz-ul-Hasan S., Amna T., Ahmed B., Verma V., Singh S., Sagar R., et al. The endophytic fungus Trametes hirsuta as a novel alternative source of podophyllotoxin and related aryltetralin ligans. J. Biotechnol. 2006;122:494-510.

    Not in our library10.1016/j.jbiotec.2005.10.015 (opens in a new tab)

  111. 111.

    Kour A., Shawl A.S., Rehman S., Sultan P., Qazi P.H., Suden P., Khajuria R.K., Verma V. Isolation and identification of an endophytic strain of Fusarium oxysporum producing podophyllotoxin from Juniperus recurva. World J. Microbiol. Biotechnol. 2008;24:1115-1121.

    Not in our library10.1007/s11274-007-9582-5 (opens in a new tab)

  112. 112.

    Cao L., Huang J., Li J. Fermentation conditions of Sinopodophyllum hexandrum endophytic fungus on production of podophyllotoxin. Food Ferment. Ind. 2007;33:28-32.

    Not in our library

  113. 113.

    Huang J.X., Zhang J., Zhang X.R., Zhang K., Zhang X., He X.R. Mucor fragilis as a novel source of the key pharmaceutical agents podophyllotoxin and kaempferol. Pharm. Biol. 2014;52:1237-1243.

    Not in our library10.3109/13880209.2014.885061 (opens in a new tab)

  114. 114.

    Nadeem M. Fusarium solani, P1, a new endophytic podophyllotoxin-producing fungus from roots of Podophyllum hexandrum. Afr. J. Microbiol. Res. 2012;6:2493-2499.

    Not in our library

  115. 115.

    Porter J., Eyberger A.L., Dondapati R. Endophyte Fungal Isolates from Podophllum peltatum Produce Podophyllotoxin. J. Nat. Prod. 2006;69:1121-1124.

    Not in our library10.1021/np060174f (opens in a new tab)

  116. 116.

    Kusari S., Zuhlke S., Spiteller M. Chemometric Evaluation of the Anti-cancer Pro-drug Podophyllotoxin and Potential Therapeutic Analogues in Juniperus and Podophyllum Species. Phytochem. Anal. 2011;22:128-143.

    Not in our library10.1002/pca.1258 (opens in a new tab)

  117. 117.

    Kusari S., Lamshoft M., Spiteller M. Aspergillus fumigatus, an endophytic fungus from Juniperus communis L. Horstmann as a novel source of the anticancer pro-drug deoxypodophyllotoxin. J. Appl. Microbiol. 2009;107:1019-1030.

    Not in our library10.1111/j.1365-2672.2009.04285.x (opens in a new tab)

  118. 118.

    Wang T., Ma Y.X., Ye Y.H., Zheng H.M., Zhang B.W., Zhang E.H. Screening and identification of endophytic fungi producing podophyllotoxin compounds in Sinopodophyllum hexandrum stems. Chin. J. Exp. Trad. Med. 2017;18:493-532.

    Not in our library

  119. 119.

    Tan X., Zhou Y., Zhou X., Xia X., Wei Y., He L., Tang H., Yu L. Diversity and bioactive potential of culturable fungal endophytes of Dysosma versipellis; a rare medicinal plant endemic to China. Sci. Rep. 2018;8:1-9.

    Not in our library10.1038/s41598-018-31009-0 (opens in a new tab)

  120. 120.

    Guo S., Jiang B., Su Y., Liu S., Zhang L. Podophyllotoxin and its analogues from the endophytic fungi derived from Dysosma veitchii. Biotechnology. 2004;14:55-57.

    Not in our library

  121. 121.

    Zeng S., Shao H., Zhang L. An endophytic fungus producing a substance analogous to podophyllotoxin isolated from Diphylleia sinensis. J. Microbiol. 2004;24:1-2.

    Not in our library

  122. 122.

    Yang X., Guo S., Zhang L., Shao H. Select of producing podophyllotoxin endophytic fungi from podophyllin plant. Nat. Prod. Res. Dev. 2003;15:419-422.

    Not in our library

  123. 123.

    Yousefzadi M., Sharifi M., Behmanesh M., Ghasempour A., Moyano E., Palazon J. The effect of light on gene expression and podophyllotoxin biosynthesis in Linum album cell culture. Plant Physiol. Biochem. 2012;56:41-46.

    Not in our library10.1016/j.plaphy.2012.04.010 (opens in a new tab)

  124. 124.

    Yang D.L., Sun P., Li M.F. Chilling temperature stimulates growth, gene over-expression and podophyllotoxin biosynthesis in Podophyllum hexandrum Royle. Plant Physiol. Biochem. 2016;9428:30231-30235.

    Not in our library10.1016/j.plaphy.2016.06.010 (opens in a new tab)

  125. 125.

    Chattopadhyay S., Mehra R.S., Srivastava A.K., Bhojwani S.S., Bisaria V.S. Effect of major nutrients on podophyllotoxin production in Podophyllum hexandrum suspension cultures. Appl. Microbiol. Biotechnol. 2003;60:541-546.

    Not in our library10.1007/s00253-002-1149-7 (opens in a new tab)

  126. 126.

    Li M.F., Li W., Yang D.L., Zhou L.L., Li T.T., Su X.M. Relationship between podophyllotoxin accumulation and soil nutrients and the influence of Fe2+ and Mn2+ on podophyllotoxin biosynthesis in Podophyllum hexandrum tissue culture. Plant Physiol. Biochem. 2013;71:96-102.

    Not in our library10.1016/j.plaphy.2013.07.001 (opens in a new tab)

  127. 127.

    Alam M.A., Naik P.K. Impact of Soil Nutrients and Environmental Factors on Podophyllotoxin Content among 28 Populations of Podophyllum Hexandrum. Commun. Soil Sci. Plant Anal. 2009;40:2485-2504.

    Not in our library10.1080/00103620903111368 (opens in a new tab)

  128. 128.

    Xu H., Lv M., Tian X. A review on hemisynthesis, biosynthesis, biological activities, mode of action, and structure-activity relationship of podophyllotoxins: 2003–2007. Curr. Med. Chem. 2009;16:327-349.

    Not in our library10.2174/092986709787002682 (opens in a new tab)

  129. 129.

    Farkya S., Bisaria V.S., Srivastava A.K. Biotechnological aspects of the production of the anticancer drug podophyllotoxin. Appl. Microbiol. Biotech. 2004;65:504-519.

    Not in our library10.1007/s00253-004-1680-9 (opens in a new tab)

  130. 130.

    Brewer C.F., Loike J.D., Horwitz S.B., Sternlicht H., Gensler W.J. Conformational analysis of podophyllotoxin and its congeners. Structure-activity relationship in microtubule assembly. J. Med. Chem. 1979;22:215-221.

    Not in our library10.1021/jm00189a001 (opens in a new tab)

  131. 131.

    Zia-Ul-Haq M., Zia-Ul-Haq M., Dewanjee S., Riaz M. Past, Present and Future of Carotenoids Research. Carotenoids: Structure and Function in the Human Body. 2021;827-854.

    Not in our library

  132. 132.

    Desbene S., Giorgi-Renault S. Drugs that inhibit tubulin polymerization: The particular case of podophyllotoxin and analogues. Curr. Med. Chem. Anti Cancer Agents. 2002;2:71-90.

    Not in our library10.2174/1568011023354353 (opens in a new tab)

  133. 133.

    Hu C., Xu D., Du W., Qian S., Wang L., Lou J., He Q., Yang B., Hu Y. Novel 4 beta-anilino-podophyllotoxin derivatives: Design synthesis and biological evaluation as potent DNA-topoisomerase II poisons and anti-MDR agents. Mol. Biosyst. 2010;6:410-420.

    Not in our library10.1039/b912336a (opens in a new tab)

  134. 134.

    Ming-Jen C., Ming D., Hing Y., Sung Y., Jih J., Hsun S., Yueh H., Gwo F., Ih S. A New Benzenoid Derivative from an Endophytic Fungus in Peperomia sui. Chem. Nat. Compd. 2018;54:625-627.

    Not in our library

  135. 135.

    Markkanen T., Makinen M.L., Nikoskelainen J., Ruohonen J., Nieminen K., Jokinen P.O., Rannio R., Hirvonen T. Biological activities of lignans. Drugs Exp. Clin. Res. 1981;7:691.

    Not in our library

  136. 136.

    Fife K.H. New treatments for genital warts less than ideal: Abstract and commentary. JAMA. 1998;279:2003-2004.

    Not in our library10.1001/jama.279.24.2003 (opens in a new tab)

  137. 137.

    Sudo K., Konno K., Shigeta S., Yokota T. Inhibitory Effects of Podophyllotoxin Derivatives on Herpes Simplex Virus Replication. Antivir. Chem. Chemother. 1998;9:263-267.

    Not in our library10.1177/095632029800900307 (opens in a new tab)

  138. 138.

    MacRae W.D., Hudson J.B., Towers G.H. The antiviral action of lignans. Planta Med. 1989;55:531-535.

    Not in our library10.1055/s-2006-962087 (opens in a new tab)

  139. 139.

    Syed T.A., Cheema K.M., Khayyami M., Ahmad S.A., Ahmad S.H., Ahmad S. Human leukocyte interferon-alpha versus podophyllotoxin in cream for the treatment of genital warts in males. A placebo-controlled, double-blind, comparative study. Dermatology. 1995;191:129.

    Not in our library10.1159/000246530 (opens in a new tab)

  140. 140.

    Beautner K.R. Podophyllotoxin in the treatment of genital warts. In EP Eischman (edn) Sexually Transmitted Diseases. Adv. Treat. 1996;24:122-232.

    Not in our library

  141. 141.

    Zhao W., Cong Y., Li H.M., Li S., Shen Y., Qi Q., Zhang Y., Li Y.Z., Tang Y.J. Challenges and potential for improving the druggability of podophyllotoxin-derived drugs in cancer chemotherapy. Nat. Prod. Rep. 2021;38:470-488.

    Not in our library10.1039/d0np00041h (opens in a new tab)

  142. 142.

    Zhang J., Liu Y.Q., Yang L., Feng G. Podophyllotoxin Derivatives Show Activity against Brontispa Longissima Larvae. Nat. Prod. Commun. 2010;5:1247-1250.

    Not in our library10.1177/1934578x1000500820 (opens in a new tab)

  143. 143.

    Leander K., Rosen B. Medicinal Uses for Podophyllotoxin. U.S. Patent. 1988.

    Not in our library

  144. 144.

    Lerndal T., Svensson B. A clinical study of CPH 82 vs. methotrexate in early rheumatoid arthritis. Rheumatology. 2000;39:316.

    Not in our library10.1093/rheumatology/39.3.316 (opens in a new tab)

  145. 145.

    Gordaliza M., Castro M.A., Miguel del Corra J.M., Feliciano S.A. Antitumor Properties of Podophyllotoxin and Related Compounds. Curr. Pharm. Des. 2000;6:1811-1839.

    Not in our library10.2174/1381612003398582 (opens in a new tab)

  146. 146.

    Hensel A., Bauer R., Heinrich M., Spiegler V., Kayser O., Hempel G., Kraft K. Challenges at the Time of COVID-19: Opportunities and innovations in the Antivirals from Nature. Planta Med. 2020;86:659-664.

    Not in our library10.1055/a-1177-4396 (opens in a new tab)

  147. 147.

    Thanh V.T.T., Pham V.C., Mai H.D.T., Litaudon M., Gueritte F., Retailleau P., Nguyen V.H., Chau V.M. Cytotoxic Lignans from Fruits of Cleistanthus indochinensis: Synthesis of Cleistantoxin Derivatives. J. Nat. Prod. 2012;75:1578-1583.

    Not in our library10.1021/np3003832 (opens in a new tab)

  148. 148.

    Nanjundaswamy N., Satishi S., Lokanatha Rai K.M., Shashikanth S., Raveesha K.A. Antibacterial Activity of Synthetic Precursors of Podophyllotoxin. Int. J. Biomed. Sci. 2007;3:112-115.

    Not in our library

  149. 149.

    Dombernowsky P., Nissen N.I. Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP 16-213 (NSC-141540) in L1210 leukemia. Acta Physiol. Microbiol. Scand. Sec. A Path. 1973;81:715-724.

    Not in our library10.1111/j.1699-0463.1973.tb03564.x (opens in a new tab)

  150. 150.

    Liu Y.Q., Feng G., Yang L., Zhang J., Li H.Y. Podophyllotoxin-derived insecticidal agents: Part XIII—Evaluation of insecticidal activity of podophyllotoxin derivatives against Brontispa longissima. Nat. Prod. Res. 2010;25:1570-1576.

    Not in our library10.1080/14786419.2010.488627 (opens in a new tab)

  151. 151.

    Wang J., Long L., Chen Y. Design, synthesis and antineoplastic activity of novel hybrids of podophyllotoxin and indirubin against human leukemia cancer cells as multifunctional anti-MDR agents. Bioorg. Med. Chem. Lett. 2018;28:1817-1824.

    Not in our library10.1016/j.bmcl.2018.04.019 (opens in a new tab)

  152. 152.

    Yang L.X. Podophyllotoxins Derivatives. U.S. Patent. 2012.

    Not in our library

  153. 153.

    Larsson O., Axelson M. New Use of Specific Cyclolignans. World Intellectual Property Organization W.O. Patent. 2002.

    Not in our library

  154. 154.

    Kerkar B., Potier P. Novel Podophyllotoxin Derivatives, the Production. There of and the Use of the Same in Therapeutics. World Intellectual Property Organization W.O. Patent. 2003.

    Not in our library

  155. 155.

    Zhang Z., Zhou M., Zhang Y. Podophyllotoxin Derivative with 4-Position Nitrogen Substitution and Preparation Method and Application There of. U.S. Patent. 2020.

    Not in our library

  156. 156.

    Kamal A., Reddy V.G., Subbarao A.V., Riyaz S., Nayak V.L., Taj S. 4Beta-Amidotriazole Linked Podophyllotoxin Derivatives as Potential Anticancer Agents. U.S. Patent. 2020.

    Not in our library

  157. 157.

    Quirion J., Deliencourt-Godefroy G.C., Audouard C. Gem-Difluorinated C-Glycoide Compounds Derived from Podophyllotoxin, Their Preparation and Their Application. U.S. Patent. 2012.

    Not in our library

  158. 158.

    Tang Y., Zhao W. 4-Sulfur Substituted Podophyllotoxin Derivative and Preparation Method There of and Use There of. U.S. Patent. 2020.

    Not in our library

  159. 159.

    Tang Y., Li J., Zhao W., Li H. Sulfur-Substituted Podophyllotoxin Derivative, Synthesis Method There of, and Use There of. U.S. Patent. 2017.

    Not in our library

  160. 160.

    Patents Lens Database.

    Not in our library

  161. 161.

    Google Patents Database.

    Not in our library

Cited by papers we hold1

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.